Navigation Links
PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
Date:5/27/2015

NEW YORK, May 27, 2015 /PRNewswire/ -- PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

Summary

The lupus therapeutics market is dominated by generics and GlaxoSmithKline's Benlysta is the only drug that has gained marketing approval for SLE in more than 50 years. Following Benlysta's launch, patients' uptake has remained low, but due to its associated high price-tag Benlysta has managed to grow the lupus market in terms of value and is currently the top-selling drug in this market, having generated approximately $265.6m in 2014 in the seven major markets. There is high R&D activity for the development of new therapies for lupus and seven promising biological therapies have the potential to enter the SLE and LN market during the 2012-2022 forecast period. The introduction of new biologic drugs will shape the future competitive landscape and drive growth in the SLE and LN markets.

Highlights

Key Questions Answered

- What was the impact of Benlysta on the lupus therapeutics market following its approval in 2011 and what is its future outlook in this market?
- What do physicians think about Rituxan following its unsuccessful Phase III trials in LN, and how will it be used off-label in lupus during the forecast period?
- What is the significance of late-phase pipeline products and how will their launch shape the future treatment landscape in SLE and LN?
- What are the significant unmet needs in the SLE and LN markets?
- What are the remaining opportunities in the SLE and LN markets?

Key Findings

- The key drivers of growth for the SLE and LN markets are the increasing uptake of GlaxoSmithKline's Benlysta, the potential launch of new biologic drugs and the increasing number of prevalent cases of SLE and LN during the 2012-2022 forecast period.
- R&D strategies include the development of me-too and first-in-class therapies, partnerships and acquisitions, and the development of products for LN.
- The lupus therapeutics market is characterized by significant unmet needs. The most pressing unmet need is the development of new therapies that will offer potent clinical benefits, have a positive safety profile and increase the available treatment options for patients.

Scope

- Overview of SLE and LN, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.
- Annualized SLE and LN therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the SLE and LN therapeutics markets.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of mid-stage pipeline drugs.
- Analysis of the current and future market competition in the global SLE and LN therapeutics markets. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global SLE and LN therapeutics markets.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global SLE and LN therapeutics markets in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global SLE and LN therapeutics markets from 2012-2022.
- Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Read the full report: http://www.reportlinker.com/p02913189-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


'/>"/>
SOURCE Reportlinker
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022
2. PharmaPoint: Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2022
3. PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022
4. PharmaPoint: Alzheimers Disease - China Drug Forecast and Market Analysis to 2022
5. PharmaPoint: Type 2 Diabetes - Brazil Drug Forecast and Market Analysis to 2022
6. PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022
7. PharmaPoint: Neuropathic Pain - Japan Drug Forecast and Market Analysis to 2022
8. PharmaPoint: Acute Coronary Syndrome - Japan Drug Forecast and Market Analysis to 2023
9. PharmaPoint: Acute Coronary Syndrome - 5EU Drug Forecast and Market Analysis to 2023
10. PharmaPoint: Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023
11. PharmaPoint: Rheumatoid Arthritis - 5EU Drug Forecast and Market Analysis to 2023
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
(Date:9/19/2017)... ANN ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical ... the precise destruction of targeted tissues, announced three leadership team developments today:   ... Josh Stopek, PhD ... ... Veteran medical device executive ...
(Date:9/12/2017)... Sept. 12, 2017   EcoVadis , the leading platform for environmental, ... first annual edition of its Global CSR Risk and Performance Index. The ... EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points across ... ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of ... collection of specialty vendors and unique items from across the nation, this holiday-themed event ... wellness services offered by the VNA. The boutique will be open Saturday, November ...
(Date:10/13/2017)... ... 13, 2017 , ... Talented host, actor Rob Lowe, is ... a new episode of "Success Files," which is an award-winning educational program broadcasted ... each subject in-depth with passion and integrity. , Sciatica occurs when the sciatic ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... services for healthcare compliance program management, will showcase a range of technology and ... for Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Hair Restoration, has recently contributed a medical article to the newly revamped ... Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit ...
Breaking Medicine News(10 mins):